Story
Prime Medicine Stock Surges After Favorable Arbitration Ruling
Shares of Prime Medicine (PRME) surged more than 11% in morning trading following the disclosure of a favorable binding arbitration ruling. The decision resolves a contractual dispute with competitor Beam Therapeutics concerning the rights to develop PM647, an investigational prime editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).
The arbitration tribunal formally declared that PM647 is within Prime Medicine’s development rights under a 2019 collaboration and license agreement between the two companies. The ruling found no breach of contract by Prime Medicine and determined that no monetary damages are owed to Beam. This outcome removes a significant legal risk that some investors had viewed as a major threat to the program's future.
With the legal dispute resolved, Prime Medicine announced its intention to file an investigational new drug (IND) application or a clinical trial application (CTA) for PM647 in the third quarter of 2026. The company anticipates releasing initial clinical data from the program in 2027.
AdThe news comes amid a series of positive developments for the company. In recent weeks, Prime Medicine received an analyst upgrade from H.C. Wainwright, an FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its PM359 program, and regulatory clearance in New Zealand for a clinical trial of PM577a. The stock's significant gains occurred on a day when major U.S. stock indices, including the S&P 500 and the Dow Jones, were trading lower.